English / فارسی
taamasrar

PHR 160 Inhaler

Use:

Labeled indications:

Clinical trials have demonstrated that PHR160 inhalation has activity for treatment of 2019-ncov lung injury. (Specially to improve oxygen saturation.)
PHR160 is not approved for prophylaxis of Covid 19.
PHR160 consist of 100% pure herbs.
Regular use of PHR160 has efficacy in shortening the duration of treatment length.

Dosage:

Adult and pediatric patients over 12 years of age:

- Mild to moderate symptoms: 1 inhalation 5 times daily (1 puff every 2 hours)
- Severe symptoms: 1 inhalation 10 times daily. (1 puff every 1 hours)

Pediatric:

Children 5 to 12 years: 1 inhalation 5 times daily (1 puff every 2 hours)
- Pediatric under 5 years: based on physician order.

Optimal duration of treatment:

Based on previous 5 days clinical stay result, the duration of treatment is 3-10 days but may expand till 3 weeks because of that optimal duration is still being studied in ongoing after completion of result of clinical and animal data studies.

Pregnancy and breast-feeding:

Consideration: limited clinical studies in pregnancy and lactation demonstrate without apparent adverse effects , however Further data are needed to confirm safety, caution should be used in pregnant and breast feeding women after physician consult.

Adverse reactions:

Like all medicines, PHR160 can cause side effects, although not everybody gets them.
Although PHR160 is well tolerated in clinical trials, if patients get any side effects, should stop taking medication and consult with physician as soon as possible.

Drug interactions:

Based on clinical trials, there are no known significant drug-drug interaction data.